Lowered ω-3 PUFAs are related to major depression, but not to somatization syndrome

Journal of Affective Disorders

Volumn 123, Issue 1-3, 2010, Pages 173-180

  Riemer, Sabine ^a   Maes, Michael ^b   Christophe, Armand ^c   Rief, Winfried ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Clinical Research Center for Mental Health of Antwerp   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

3 PUFAs; 6 PUFA; Depression; DHA; EPA; Somatization syndrome

Indexed keywords

ARACHIDONIC ACID; CD8 ANTIGEN; CHOLESTEROL ESTER; CLARA CELL PROTEIN; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SEROTONIN;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; FATTY ACID ANALYSIS; FEMALE; GERMANY; HUMAN; IMMUNE SYSTEM; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SOMATIZATION; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS;

ADULT; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; SOMATOFORM DISORDERS; STATISTICS AS TOPIC;

EID: 77952237907     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2009.08.004     Document Type: Article

References (76)

1. Adams P.B., Lawson S., Sanigorski A., and Sinclair A.J. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31 (1996) 157-161 Suppl
2. Appleton K.M., Hayward R.C., Gunnell D., Peters T.J., Rogers P.J., Kessler, D., Ness, and A.R. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am. J. Clin. Nutr. 84 (2006) 1308-1316
3. Barsky A.J., Orav E.J., and Bates D.W. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch. Gen. Psychiatry 62 (2005) 903-910
4. Beck A.T., Ward C., and Mendelson M. Beck Depression Inventory (BDI). Arch. Gen. Psychiatry 4 (1961) 561-571
5. Carney R.M., and Freedland K.E. Depression in patients with coronary heart disease. Am. J. Med. 121 (2008) S20-27
6. Conklin S.M., Manuck S.B., Yao J.K., Flory J.D., Hibbeln J.R., and Muldoon M.F. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom. Med. 69 (2007) 932-934
7. Cuijpers P., and Smit F. Excess mortality in depression: a meta-analysis of community studies. J. Affect. Disord. 72 (2002) 227-236
8. Das S., and O'Keefe J.H. Behavioral cardiology: recognizing and addressing the profound impact of psychosocial stress on cardiovascular health. Curr. Hypertens. Rep. 10 (2008) 374-381
9. Delion S., Chalon S., Guilloteau D., Besnard J.C., and Durand G. alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J. Neurochem. 66 (1996) 1582-1591
10. De Vriese S.R., Christophe A.B., and Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. 73 (2003) 3181-3187
11. Dieperink E., Willenbring M., and Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am. J. Psychiatry 157 (2000) 867-876
12. Dinan T.G., Clarke G., Quigley E.M., Scott L.V., Shanahan F., Cryan J., Cooney J., and Keeling P.W. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am. J. Gastroenterol. 103 (2008) 2570-2576
13. Escobar J.I., Rubio-Stipec M., Canino G., and Karno M. Somatic symptom index (SSI): a new and abridged somatization construct. Prevalence and epidemiological correlates in two large community samples. J. Nerv. Ment. Dis. 177 (1989) 140-146
14. Frasure-Smith N., Lesperance F., and Julien P. Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biol. Psychiatry 55 (2004) 891-896
15. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., Keck P.E., Mayangell L.B., Richardson A.J., Lake J., and Stoll A.L. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 67 (2006) 1954-1967
16. Group C.-N.C. The changing rate of major depression: cross-national comparisons. J. Am. Med. Assoc. 268 (1992) 3098-3105
17. Haag M. Essential fatty acids and the brain. Can. J. Psychiatry 48 (2003) 195-203
18. Hibbeln J.R., Linnoila M., Umhau J.C., Rawlings R., George D.T., and Salem Jr. N. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol. Psychiatry 44 (1998) 235-242
19. Hibbeln J.R., Ferguson T.A., and Blasbalg T.L. Omega-3 fatty acid deficiencies in neurodevelopment, aggression and autonomic dysregulation: opportunities for intervention. Int. Rev. Psychiatry 18 (2006) 107-118
20. Hiller W., Zaudig M., and Mombour W. Internationale Diagnosen Checklisten (IDCL) für DSM-IV, Göttingen (1997)
21. Huan M., Hamazaki K., Sun Y., Itomura M., Liu H., Kang W., Watanabe S., Terasawa K., and Hamazaki T. Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China. Biol. Psychiatry 56 (2004) 490-496
22. Huang S.Y., Yang H.T., Chiu C.C., Pariante C.M., and Su K.P. Omega-3 fatty acids on the forced-swimming test. J. Psychiatr. Res. 42 (2008) 58-63
23. Kiecolt-Glaser J.K., Belury M.A., Porter K., Beversdorf D.Q., Lemeshow S., and Glaser R. Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults. Psychosom. Med. 69 (2007) 217-224
24. Kirmayer L.J., and Robbins J.M. Three forms of somatization in primary care: prevalence, co-occurrence, and sociodemographic characteristics. J. Nerv. Ment. Dis. 179 (1991) 647-655
25. Kitzlerova E., and Anders M. The role of some new factors in the pathophysiology of depression and cardiovascular disease: overview of recent research. Neuroendocrinol. Lett. 28 (2007) 832-840
26. Konsman J.P., Parnet P., and Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 25 (2002) 154-159
27. Kris-Etherton P.M., Harris W.S., and Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106 (2002) 2747-2757
28. Kroenke K., and Rosmalen J.G. Symptoms, syndromes, and the value of psychiatric diagnostics in patients who have functional somatic disorders. Med. Clin. North Am. 90 (2006) 603-626
29. Lichtman J.H., Bigger Jr. J.T., Blumenthal J.A., Frasure-Smith N., Kaufmann P.G., Lesperance F., Mark D.B., Sheps D.S., Taylor C.B., and Froelicher E.S. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 118 (2008) 1768-1775
30. Maes M. A review on the acute phase response in major depression. Rev. Neurosci. 4 (1993) 407-416
31. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol. Lett. 29 (2008) 287-291
32. Maes M., Bosmans E., Suy E., Vandervorst C., DeJonckheere C., and Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr. Scand. 84 (1991) 379-386
33. Maes M., Stevens W.J., Declerck L.S., Bridts C.H., Peeters D., Schotte C., and Cosyns P. Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: further evidence for an inflammatory process during that illness. Prog. Neuropsychopharmacol. Biol. Psychiatry 17 (1993) 241-255
34. Maes M., Delanghe J., Meltzer H.Y., Scharpe S., D'Hondt P., and Cosyns P. Lower degree of esterification of serum cholesterol in depression: relevance for depression and suicide research. Acta Psychiatr. Scand. 90 (1994) 252-258
35. Maes M., Smith R., Christophe A., Cosyns P., Desnyder R., and Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J. Affect. Disord. 38 (1996) 35-46
36. Maes M., Bosmans E., De Jongh R., Kenis G., Vandoolaeghe E., and Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9 (1997) 853-858
37. Maes M., De Vos N., Demedts P., Wauters A., and Neels H. Lower serum zinc in major depression in relation to changes in serum acute phase proteins. J. Affect. Disord. 56 (1999) 189-194
38. Maes M., Mihaylova I., and Bosmans E. Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol. Lett. 28 (2007) 456-462
39. Maes M., Mihaylova I., Kubera M., and Bosmans E. Why fish oils may not always be adequate treatments for depression or other inflammatory illnesses: docosahexaenoic acid, an omega-3 polyunsaturated fatty acid, induces a Th-1-like immune response. Neuro Endocrinol. Lett. 28 (2007) 875-880
40. Makrides M., Crowther C.A., Gibson R.A., Gibson R.S., and Skeaff C.M. Docosahexaenoic acid and post-partum depression - is there a link?. Asia Pac. J. Clin. Nutr. 12 (2003) S37 Suppl
41. Mamalakis G., Tornaritis M., and Kafatos A. Depression and adipose essential polyunsaturated fatty acids. Prostaglandins Leukot. Essent. Fat. Acids 67 (2002) 311-318
42. McNamara R.K., Hahn C.G., Jandacek R., Rider T., Tso P., Stanford K.E., and Richtand N.M. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol. Psychiatry 62 (2007) 17-24
43. Nemets B., Stahl Z., and Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry 159 (2002) 477-479
44. Nordin H., Eisemann M., and Richter J. The accuracy of the DSM-IV pain disorder and the ICD-10 persistent somatoform pain disorder in chronic pain patients. J. Clin. Psychol. Med. Settings 13 (2006) 307-314
45. Owen C., Rees A.M., and Parker G. The role of fatty acids in the development and treatment of mood disorders. Curr. Opin. Psychiatry 21 (2008) 19-24
46. Parker G., Gibson N.A., Brotchie H., Heruc G., Rees A.M., and Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am. J. Psychiatry 163 (2006) 969-978
47. Peet M., and Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry 59 (2002) 913-919
48. Peet M., Murphy B., Shay J., and Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol. Psychiatry 43 (1998) 315-319
49. Raison C.L., Demetrashvili M., Capuron L., and Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19 (2005) 105-123
50. Rief W., and Barsky A.J. Psychobiological perspectives on somatoform disorders. Psychoneuroendocrinology 30 (2005) 996-1002
51. Rief W., Shaw R., and Fichter M.M. Elevated levels of psychophysiological arousal and cortisol in patients with somatization syndrome. Psychosom. Med. 60 (1998) 198-203
52. Rief W., and Hiller W. Toward empirically based criteria for the classification of somatoform disorders. J. Psychosom. Res. 46 (1999) 507-518
53. Rief W., Hiller W., and Heuser J. Das Screening für Somatoforme Störungen (1997) Manual., Bern.
54. Rief W., Heuser J., Mayrhuber E., Stelzer I., Hiller W., and Fichter M.M. The classification of multiple somatoform symptoms. J. Nerv. Ment. Dis. 184 (1996) 680-687
55. Rief W., Hessel A., and Braehler E. Somatization symptoms and hypochondriacal features in the general population. Psychosom. Med. 63 (2001) 595-602
56. Rief W., Pilger F., Ihle D., Bosmans E., Egyed B., and Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res. 105 (2001) 165-174
57. Rief W., Pilger F., Ihle D., Verkerk R., Scharpe S., and Maes M. Psychobiological aspects of somatoform disorders: contributions of monoaminergic transmitter systems. Neuropsychobiology 49 (2004) 24-29
58. Rief W., Zenz M., Schweiger U., Ruddel H., Henningsen P., and Nilges P. Redefining (somatoform) pain disorder in ICD-10: a compromise of different interest groups in Germany. Curr. Opin. Psychiatry 21 (2008) 178-181
59. Rogers P.J., Appleton K.M., Kessler D., Peters T.J., Gunnell D., Hayward R.C., Heatherley S.V., Christian L.M., Mcnaughton S.A., and Ness A.R. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br. J. Nutr. 99 (2008) 421-431
60. Ross B.M. ω-3 Fatty acid deficiency in major depressive disorder is caused by the interaction between diet and a genetically determined abnormality in phospholipid metabolism. Med. Hypotheses 68 (2007) 515-524
61. Ross B.M., and Glen I. Prostaglandins and eicosanoids in the CNS. In: Curtis-Prior P. (Ed). The Eicosanoids. (2nd ed.) (2004), Wiley, London 434-441
62. Ross B.M., Seguin J., and Sieswerda L.E. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?. Lipids Health Dis. 6 (2007) 21
63. Severus W.E., Littman A.B., and Stoll A.L. Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv. Rev. Psychiatry 9 (2001) 280-293
64. Silvers K.M., Wolley C.C., Hamilton F.C., Watts P.M., and Watson R.A. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot. Essent. Fat. Acids 72 (2005) 211-218
65. Sinclair A.J., Begg D., Mathai M., and Weisinger R.S. Omega 3 fatty acids and the brain: review of studies in depression. Asia Pac J Clin Nutr 16 Suppl 1 (2007) 391-397
66. Su K.P. Mind-body interface: the role of n-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness comorbidity of depression. Asia Pac. J. Clin. Nutr. 17 (2008) 151-157
67. Su K.P. Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a 'mind-body interface'?. Neurosignals 17 (2009) 144-152
68. Su K.P., H.S.Y., Chiu C.C., and Shen W.W. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 13 (2003) 267-271
69. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr. Scand. 118 (2008) 434-442
70. van Zyl L.T., Hasegawa T., and Nagata K. Effects of antidepressant treatment on heart rate variability in major depression: a quantitative review. Biopsychosoc. Med. 2 (2008) 12
71. Wessely S., Nimnuan C., and Sharpe M. Functional somatic syndromes: one or many?. Lancet 354 (1999) 936-939
72. Wittchen, H.U., Zaudig, M. & Fydrich, T., 1997. SKID. Strukturiertes Klinisches Interview für DSM-IV. Achse I und II. Handanweisung., Göttingen.
73. Yaqoob, P., 2003. Fatty acids and the immune system: from basic science to clinical applications. Proc. Nutr. Soc. (2004), 63, 89-104 63, 89-104.
74. Young G., and Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod. Nutr. Dev. 45 (2005) 1-28
75. Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod. Nutr. Dev. 44 (2004) 273-282
76. Zhang J., and Li Y. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial - comments by Zhang and Li. Br. J. Nutr. (2008) 10.1017/S0007114508975644